PharmAust Limited

PAA

AU000000PAA1

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:38 2024-05-17 am EDT			5-day change	1st Jan Change
0.185 ^AUD	0.00%		+8.82%	+60.87%

04:00am	PharmAust Appoints Nonexecutive Chair; Shares Up 3%	MT
03:09am	PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	MT

PharmAust Limited Announces Cessation of David Morris as Director

October 27, 2015 at 05:25 pm EDT

PharmAust Limited announced that David Morris ceased to be director of the company on 27 October 2015.

Latest news about PharmAust Limited

PharmAust Appoints Nonexecutive Chair; Shares Up 3%	10:00pm	MT
PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	09:09pm	MT
Pharmaust Appoints Interim Chair, Managing Director; Shares Fall 16%	May. 08	MT
Pharmaust CEO Resigns	Apr. 22	MT
PharmAust Obtains Approval to Commence Monepantel Extension Study	Apr. 09	MT
PharmAust Retracts CEO Statement from Media	Apr. 02	MT
PharmAust Submits Supporting Data to US FDA for Monepantel Orphan Drug Designation Request; Shares Down 7%	Mar. 13	MT
PharmAust Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29	CI
PharmAust Gets US FDA Guidance for Motor Neuron Disease Medication	Feb. 16	MT
PharmAust Appoints Non-Executive Director	Feb. 07	MT
PharmAust Secures Ethics Approval for Phase One Motor Neuron Disease Extension Study; Shares Rise 6%	Jan. 29	MT
PharmAust to Amend Monepantel Orphan Drug Designation Request to FDA	Jan. 28	MT
PharmAust Ties Up with Berry Consultants for Upcoming Phase 2/3 Motor Neuron Disease Trial; Shares Rise 4%	Jan. 15	MT
PharmAust Secures Meeting with US FDA for Motor Neuron Disease Drug Application; Shares Jump 9%	Jan. 01	MT
PharmAust Secures Support for Phase 2/3 Clinical Trial Grant Request	Dec. 25	MT
PharmAust Secures R&D Tax Refund for Fiscal Year 2023	Dec. 20	MT
PharmAust Achieves 93% take Up on Options Offer	Dec. 15	MT
PharmAust to Raise AU$3.5 Million From Share Sale	Dec. 14	MT
PharmAust Concludes Phase One Study for Motor Neuron Disease Medication	Nov. 30	MT
Pharmaust Completes Dosing for All Cohort Four Patients in Phase One Study of Motor Neurone Disease; Shares Rise 3%	23-10-13	MT
PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023	23-08-27	CI
PharmAust Limited Announces Executive Changes	23-08-27	CI
PharmAust Concludes Pharmacokinetics Study in Third Group of MND Patients	23-08-09	MT
PharmAust Subsidiary Enters Voluntary Liquidation	23-08-01	MT

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Companyâs segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.

Sector

Pharmaceuticals

Calendar

09:00pm - Business Update Call

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMAUST LIMITED	+60.87%	48.8M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+29.84%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.53%	239B
ROCHE HOLDING AG	-3.19%	209B
NOVARTIS AG	+10.09%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals